 Franklin Wright
Concepts (196)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Wounds and Injuries | 20 | 2026 | 897 | 2.490 |
Why?
| | Blood Transfusion | 10 | 2025 | 393 | 1.380 |
Why?
| | Trauma Centers | 8 | 2026 | 450 | 1.350 |
Why?
| | Resuscitation | 6 | 2024 | 283 | 1.060 |
Why?
| | Hemorrhage | 5 | 2025 | 760 | 0.910 |
Why?
| | Venous Thromboembolism | 3 | 2025 | 337 | 0.900 |
Why?
| | Blood Component Transfusion | 4 | 2025 | 96 | 0.860 |
Why?
| | Venous Thrombosis | 2 | 2025 | 192 | 0.830 |
Why?
| | Hypocalcemia | 4 | 2026 | 35 | 0.780 |
Why?
| | Shock, Hemorrhagic | 3 | 2024 | 191 | 0.730 |
Why?
| | Altitude | 1 | 2025 | 476 | 0.670 |
Why?
| | Blood Coagulation Tests | 1 | 2020 | 73 | 0.640 |
Why?
| | Trauma Severity Indices | 1 | 2019 | 111 | 0.600 |
Why?
| | Thromboembolism | 1 | 2020 | 118 | 0.600 |
Why?
| | Extremities | 1 | 2019 | 140 | 0.580 |
Why?
| | Fibrinolysis | 1 | 2020 | 161 | 0.570 |
Why?
| | Injury Severity Score | 7 | 2025 | 560 | 0.540 |
Why?
| | Plasma | 1 | 2018 | 221 | 0.520 |
Why?
| | Stroke | 2 | 2023 | 1158 | 0.510 |
Why?
| | Triage | 1 | 2018 | 246 | 0.480 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 374 | 0.450 |
Why?
| | Coronavirus Infections | 1 | 2020 | 371 | 0.450 |
Why?
| | Transfusion Reaction | 2 | 2025 | 62 | 0.390 |
Why?
| | Quality Improvement | 6 | 2025 | 1254 | 0.390 |
Why?
| | Interleukin-1beta | 1 | 2014 | 386 | 0.380 |
Why?
| | Myocardial Infarction | 2 | 2017 | 1069 | 0.380 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2014 | 1250 | 0.360 |
Why?
| | Adult | 26 | 2026 | 39391 | 0.360 |
Why?
| | England | 3 | 2023 | 108 | 0.360 |
Why?
| | Cardiovascular Diseases | 1 | 2023 | 2096 | 0.340 |
Why?
| | Middle Aged | 21 | 2026 | 34647 | 0.330 |
Why?
| | Heart Failure | 1 | 2023 | 2093 | 0.320 |
Why?
| | Tissue Plasminogen Activator | 2 | 2021 | 239 | 0.310 |
Why?
| | Calcium | 3 | 2026 | 1192 | 0.310 |
Why?
| | Retrospective Studies | 14 | 2025 | 16374 | 0.310 |
Why?
| | Pandemics | 3 | 2023 | 1656 | 0.290 |
Why?
| | Hospitalization | 2 | 2022 | 2264 | 0.290 |
Why?
| | Oxygen | 2 | 2026 | 992 | 0.290 |
Why?
| | Saline Solution, Hypertonic | 3 | 2014 | 41 | 0.280 |
Why?
| | Transcription, Genetic | 1 | 2014 | 1487 | 0.280 |
Why?
| | Male | 26 | 2026 | 70179 | 0.260 |
Why?
| | ABO Blood-Group System | 2 | 2024 | 53 | 0.260 |
Why?
| | Registries | 3 | 2024 | 2144 | 0.250 |
Why?
| | Humans | 36 | 2026 | 141754 | 0.250 |
Why?
| | Electronic Health Records | 2 | 2025 | 1132 | 0.240 |
Why?
| | Hypercalcemia | 1 | 2026 | 23 | 0.240 |
Why?
| | Female | 24 | 2026 | 75943 | 0.240 |
Why?
| | Wounds, Penetrating | 2 | 2019 | 71 | 0.230 |
Why?
| | Wound Infection | 1 | 2025 | 37 | 0.230 |
Why?
| | Antibiotic Prophylaxis | 1 | 2025 | 122 | 0.210 |
Why?
| | Liver Transplantation | 3 | 2024 | 768 | 0.210 |
Why?
| | Aged | 15 | 2025 | 24746 | 0.210 |
Why?
| | Thoracostomy | 1 | 2004 | 19 | 0.210 |
Why?
| | Vital Signs | 1 | 2024 | 47 | 0.210 |
Why?
| | Partial Thromboplastin Time | 2 | 2021 | 53 | 0.210 |
Why?
| | Airway Management | 1 | 2024 | 71 | 0.210 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2026 | 184 | 0.210 |
Why?
| | Lung | 2 | 2014 | 4137 | 0.210 |
Why?
| | Inflammation | 1 | 2014 | 2902 | 0.200 |
Why?
| | Hemostatics | 1 | 2004 | 58 | 0.200 |
Why?
| | Propensity Score | 1 | 2025 | 332 | 0.200 |
Why?
| | Wounds, Gunshot | 2 | 2019 | 248 | 0.190 |
Why?
| | Pulmonary Embolism | 1 | 2024 | 239 | 0.180 |
Why?
| | Intubation, Intratracheal | 1 | 2024 | 288 | 0.180 |
Why?
| | Advance Directives | 1 | 2022 | 81 | 0.170 |
Why?
| | Risk Factors | 6 | 2025 | 10482 | 0.170 |
Why?
| | Aged, 80 and over | 5 | 2022 | 7923 | 0.170 |
Why?
| | Hypoxia | 2 | 2026 | 1165 | 0.170 |
Why?
| | Fibrin Clot Lysis Time | 1 | 2020 | 10 | 0.170 |
Why?
| | Sex Distribution | 2 | 2019 | 381 | 0.160 |
Why?
| | Feasibility Studies | 1 | 2024 | 1027 | 0.160 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2020 | 93 | 0.160 |
Why?
| | Thrombelastography | 1 | 2020 | 175 | 0.150 |
Why?
| | Sepsis | 1 | 2025 | 621 | 0.140 |
Why?
| | Critical Illness | 2 | 2021 | 837 | 0.140 |
Why?
| | NF-kappa B | 2 | 2014 | 692 | 0.140 |
Why?
| | Cerebrovascular Disorders | 1 | 2019 | 97 | 0.140 |
Why?
| | Western Australia | 1 | 2017 | 9 | 0.140 |
Why?
| | Respiratory Insufficiency | 1 | 2021 | 325 | 0.140 |
Why?
| | Thrombosis | 1 | 2021 | 399 | 0.130 |
Why?
| | Betacoronavirus | 1 | 2020 | 276 | 0.130 |
Why?
| | Clinical Protocols | 1 | 2018 | 273 | 0.130 |
Why?
| | Information Storage and Retrieval | 1 | 2017 | 120 | 0.130 |
Why?
| | Age Distribution | 1 | 2017 | 397 | 0.130 |
Why?
| | Emergency Medical Services | 2 | 2024 | 650 | 0.130 |
Why?
| | Military Personnel | 1 | 2024 | 615 | 0.130 |
Why?
| | Sensitivity and Specificity | 2 | 2019 | 1977 | 0.130 |
Why?
| | Emergency Service, Hospital | 2 | 2026 | 2193 | 0.120 |
Why?
| | Violence | 1 | 2019 | 276 | 0.120 |
Why?
| | Renal Dialysis | 1 | 2020 | 457 | 0.120 |
Why?
| | Epithelial Cells | 2 | 2014 | 1114 | 0.120 |
Why?
| | Regression Analysis | 1 | 2017 | 1023 | 0.110 |
Why?
| | Anti-Bacterial Agents | 1 | 2025 | 1866 | 0.110 |
Why?
| | Transcription Factor RelA | 1 | 2014 | 85 | 0.110 |
Why?
| | Intensive Care Units | 1 | 2020 | 871 | 0.110 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 2075 | 0.100 |
Why?
| | Time Factors | 3 | 2024 | 6966 | 0.100 |
Why?
| | Oximetry | 2 | 2026 | 127 | 0.100 |
Why?
| | Incidence | 4 | 2026 | 2806 | 0.100 |
Why?
| | Matrix Metalloproteinase 13 | 1 | 2012 | 24 | 0.100 |
Why?
| | Phosphorylation | 2 | 2014 | 1774 | 0.090 |
Why?
| | Cell Line | 2 | 2014 | 2887 | 0.090 |
Why?
| | Prospective Studies | 4 | 2026 | 7777 | 0.080 |
Why?
| | Young Adult | 6 | 2025 | 13749 | 0.080 |
Why?
| | Colorado | 1 | 2019 | 4629 | 0.070 |
Why?
| | Acute Lung Injury | 1 | 2012 | 304 | 0.070 |
Why?
| | Guideline Adherence | 2 | 2025 | 566 | 0.070 |
Why?
| | Hepatitis, Autoimmune | 1 | 2008 | 15 | 0.070 |
Why?
| | Survivors | 1 | 2012 | 504 | 0.070 |
Why?
| | Liver Failure | 1 | 2008 | 80 | 0.070 |
Why?
| | Respiration, Artificial | 2 | 2022 | 685 | 0.060 |
Why?
| | Adolescent | 6 | 2025 | 22130 | 0.060 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2025 | 37 | 0.060 |
Why?
| | Adrenal Cortex Hormones | 1 | 2008 | 501 | 0.060 |
Why?
| | Multicenter Studies as Topic | 1 | 2026 | 363 | 0.050 |
Why?
| | United States Department of Defense | 1 | 2024 | 17 | 0.050 |
Why?
| | Data Interpretation, Statistical | 1 | 2026 | 377 | 0.050 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2007 | 353 | 0.050 |
Why?
| | Calcium, Dietary | 1 | 2023 | 57 | 0.050 |
Why?
| | Tracheostomy | 1 | 2024 | 142 | 0.050 |
Why?
| | Treatment Outcome | 4 | 2024 | 11181 | 0.050 |
Why?
| | Signal Transduction | 1 | 2014 | 5169 | 0.040 |
Why?
| | Reoperation | 1 | 2004 | 592 | 0.040 |
Why?
| | Infant | 3 | 2024 | 9843 | 0.040 |
Why?
| | Liver Neoplasms | 1 | 2007 | 741 | 0.040 |
Why?
| | Hyperoxia | 1 | 2021 | 91 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2021 | 5212 | 0.040 |
Why?
| | Patient Outcome Assessment | 1 | 2021 | 131 | 0.040 |
Why?
| | Anticoagulants | 1 | 2025 | 675 | 0.040 |
Why?
| | Child, Preschool | 3 | 2024 | 11512 | 0.040 |
Why?
| | Survival Rate | 1 | 2024 | 1972 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2026 | 1634 | 0.040 |
Why?
| | Research Design | 1 | 2026 | 1146 | 0.040 |
Why?
| | Fibrinolytic Agents | 1 | 2021 | 284 | 0.040 |
Why?
| | Homicide | 1 | 2019 | 66 | 0.040 |
Why?
| | World Health Organization | 1 | 2019 | 126 | 0.040 |
Why?
| | Terminal Care | 1 | 2022 | 252 | 0.030 |
Why?
| | Databases, Factual | 1 | 2024 | 1448 | 0.030 |
Why?
| | Obesity | 2 | 2024 | 3008 | 0.030 |
Why?
| | Europe | 1 | 2019 | 411 | 0.030 |
Why?
| | Decision Support Systems, Clinical | 1 | 2021 | 263 | 0.030 |
Why?
| | Hospital Mortality | 1 | 2022 | 924 | 0.030 |
Why?
| | Intracranial Hemorrhages | 1 | 2018 | 94 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2025 | 1570 | 0.030 |
Why?
| | United Kingdom | 1 | 2018 | 322 | 0.030 |
Why?
| | Length of Stay | 1 | 2022 | 1263 | 0.030 |
Why?
| | Pilot Projects | 1 | 2021 | 1826 | 0.030 |
Why?
| | Life Style | 1 | 2018 | 482 | 0.030 |
Why?
| | Child | 3 | 2024 | 22414 | 0.030 |
Why?
| | Decision Making | 1 | 2022 | 961 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2019 | 6289 | 0.030 |
Why?
| | United States | 2 | 2024 | 15310 | 0.030 |
Why?
| | Brain Ischemia | 1 | 2018 | 350 | 0.030 |
Why?
| | Immunosuppressive Agents | 2 | 2008 | 855 | 0.020 |
Why?
| | Nebulizers and Vaporizers | 1 | 2012 | 68 | 0.020 |
Why?
| | Neutrophil Infiltration | 1 | 2012 | 108 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2012 | 187 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2024 | 2821 | 0.020 |
Why?
| | Medical Record Linkage | 1 | 2012 | 68 | 0.020 |
Why?
| | Random Allocation | 1 | 2012 | 367 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2024 | 5974 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 2012 | 594 | 0.020 |
Why?
| | Secondary Prevention | 1 | 2012 | 241 | 0.020 |
Why?
| | Smoking | 1 | 2018 | 1603 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 5697 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2012 | 910 | 0.020 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2012 | 650 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 2018 | 1077 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2012 | 1268 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2012 | 1739 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2012 | 1317 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2009 | 418 | 0.020 |
Why?
| | Protein Transport | 1 | 2009 | 448 | 0.020 |
Why?
| | Comorbidity | 1 | 2012 | 1664 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2012 | 2525 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2008 | 718 | 0.020 |
Why?
| | Blotting, Western | 1 | 2009 | 1234 | 0.020 |
Why?
| | Chemoembolization, Therapeutic | 1 | 2007 | 88 | 0.020 |
Why?
| | Blood Vessels | 1 | 2007 | 180 | 0.010 |
Why?
| | Cell Survival | 1 | 2009 | 1134 | 0.010 |
Why?
| | Neoplasm Invasiveness | 1 | 2007 | 510 | 0.010 |
Why?
| | Sirolimus | 1 | 2007 | 277 | 0.010 |
Why?
| | Recurrence | 1 | 2008 | 1111 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2009 | 1197 | 0.010 |
Why?
| | Age Factors | 1 | 2012 | 3294 | 0.010 |
Why?
| | Preoperative Care | 1 | 2007 | 372 | 0.010 |
Why?
| | Survival Analysis | 1 | 2007 | 1320 | 0.010 |
Why?
| | Rats | 1 | 2012 | 5637 | 0.010 |
Why?
| | Prognosis | 1 | 2012 | 4080 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 2007 | 1401 | 0.010 |
Why?
| | Risk Assessment | 1 | 2012 | 3508 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2012 | 4421 | 0.010 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2007 | 1078 | 0.010 |
Why?
| | Liver | 1 | 2007 | 1820 | 0.010 |
Why?
| | Cohort Studies | 1 | 2008 | 5815 | 0.010 |
Why?
| | Animals | 1 | 2012 | 37749 | 0.000 |
Why?
|
|
Wright's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|